NCT05152680View on ClinicalTrials.gov

Mass Balance Study of NV-5138 in Healthy Male Subjects.

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

November 11, 2021

Primary Completion Date

December 9, 2021

Study Completion Date

December 9, 2021

Conditions
Healthy Volunteers
Interventions
DRUG

[14C]-NV-5138

Single dose, given as oral solution, 1600 mg

Trial Locations (1)

NG116JS

Quotient Sciences, Ruddington

Sponsors
All Listed Sponsors
collaborator

Supernus Pharmaceuticals, Inc.

INDUSTRY

lead

Navitor Pharmaceuticals, Inc.

INDUSTRY

NCT05152680 - Mass Balance Study of NV-5138 in Healthy Male Subjects. | Biotech Hunter | Biotech Hunter